▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Clementia Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $26.35.
The current consensus among 0 investment analysts is to n/a stock in Clementia Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Hold consensus rating.
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.